• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • OEM Prohibited Medical Devices in China – Catalogue Finalized

OEM Prohibited Medical Devices in China – Catalogue Finalized

OEM prohibited medical devices
Monday, 25 April 2022 / Published in Medical Device, News, NMPA Registration in China

OEM Prohibited Medical Devices in China – Catalogue Finalized

OEM prohibited medical devices means original equipment manufacturers (OEM) are banned from production in China for certain medical devices. On March 24, 2022, the NMPA announced (No.17-2022) the the latest finalized version of the product catalogue prohibiting certain products sold in China from being manufactured by an OEM.

According to the Order 739 implemented in June 1, 2021, in general the registrants and filers at NMPA can self-manufacture medical devices or entrust a qualified manufacturer or OEM for production. However, the Order 739 specified that the manufacturing of high-risk medical implants cannot be entrusted to other parties. Read our separate blog post for more information about the Order 739.

OEM Prohibited Medical Devices – Catalogue Highlights

Key highlights of the catalogue update prohibiting certain high-risk products from OEM production are summarised by our regulatory experts below.

  • As compared to the 2017 edition of the catalogue, implantable insulin pumps, surgical hemostatic materials, etc. will no longer be prohibited due to a more developed production process now in China and relatively low risk in the market.
  • The new catalogue covers 3 types of active implantable devices (e.g. implantable cardiac pacemakers) and 9 types of passive implantable devices (e.g. intracranial stent systems), as well as allogeneic implantable medical device and implantable medical devices with animal tissue origin.
  • For comparison between the 2014 version and 2022 version, please refer to the following catalogues:
    • Catalogue of OEM Prohibited Medical Devices (2014)
    • Catalogue of OEM Prohibited Medical Devices (2022)
  • According to the guideline for writing OEM quality agreements in China (No.20-2022), OEM manufacturers and the registrants will be required to sign the OEM quality agreement specifying the obligations and responsibilities of both sides.
  • Read our separate blog post about the draft catalogue issued on November 19, 2021. The finalized catalogue had some products removed from the draft catalogue including, but not limited to the following:
    • Implantable cardioverter defibrillator
    • Intracranial embolization equipment
    • Intracranial coil system
    • Tissue engineered biological amniotic membrane

By Jacky Li. If you would like to learn more about our localization services in China for original equipment manufacturer (OEM) or market holder authorization (MAH) or our registration and CRO services for medical devices, IVDs, pharmaceuticals, cosmetics or other products, please contact Cisema.

Tagged under: Medical Devices, OEM production

What you can read next

NMPA issues updated guidance for registration of AI software to assist with responding to the Corona-virus pandemic
Automotive Implementation Rules for CCC-Certification Revised
Guidelines for Reporting Adverse Events

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.